1.53
Schlusskurs vom Vortag:
$1.47
Offen:
$1.46
24-Stunden-Volumen:
603.60K
Relative Volume:
0.75
Marktkapitalisierung:
$93.92M
Einnahmen:
$5.03M
Nettoeinkommen (Verlust:
$-185.41M
KGV:
-0.4951
EPS:
-3.09
Netto-Cashflow:
$-139.79M
1W Leistung:
+0.67%
1M Leistung:
-5.66%
6M Leistung:
+11.94%
1J Leistung:
-89.01%
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Firmenname
Pliant Therapeutics Inc
Sektor
Branche
Telefon
650-481-6770
Adresse
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Vergleichen Sie PLRX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
PLRX
Pliant Therapeutics Inc
|
1.53 | 90.24M | 5.03M | -185.41M | -139.79M | -3.09 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
408.60 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
472.79 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.54 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
801.70 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
331.41 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-10-10 | Herabstufung | JP Morgan | Neutral → Underweight |
2025-03-04 | Fortgesetzt | Cantor Fitzgerald | Neutral |
2025-03-04 | Herabstufung | Needham | Buy → Hold |
2025-03-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
2025-03-03 | Herabstufung | Stifel | Buy → Hold |
2025-02-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
2025-02-10 | Herabstufung | Citigroup | Buy → Neutral |
2025-02-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2025-02-10 | Herabstufung | JP Morgan | Overweight → Neutral |
2025-02-10 | Herabstufung | Oppenheimer | Outperform → Perform |
2025-02-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2025-02-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
2023-05-18 | Eingeleitet | Canaccord Genuity | Buy |
2023-04-13 | Eingeleitet | Robert W. Baird | Outperform |
2022-12-14 | Eingeleitet | Stifel | Buy |
2022-12-07 | Eingeleitet | JP Morgan | Overweight |
2022-09-01 | Eingeleitet | Citigroup | Buy |
2022-07-20 | Eingeleitet | SVB Leerink | Outperform |
2022-05-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
2021-11-24 | Eingeleitet | RBC Capital Mkts | Outperform |
2021-11-03 | Eingeleitet | H.C. Wainwright | Buy |
2021-04-20 | Eingeleitet | BTIG Research | Buy |
2021-04-05 | Eingeleitet | Citigroup | Buy |
2020-06-29 | Eingeleitet | Citigroup | Buy |
2020-06-29 | Eingeleitet | Cowen | Outperform |
2020-06-29 | Eingeleitet | Needham | Buy |
2020-06-29 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Pliant Therapeutics Inc Aktie (PLRX) Neueste Nachrichten
Can Pliant Therapeutics Inc. stock maintain operating marginsJuly 2025 Fed Impact & Fast Entry High Yield Stock Tips - newser.com
Pliant Therapeutics Inc. stock trend forecast2025 Investor Takeaways & Capital Efficiency Focused Strategies - newser.com
Has Pliant Therapeutics Inc. found a price floorJuly 2025 Analyst Calls & Low Risk Investment Opportunities - newser.com
What to expect from Pliant Therapeutics Inc. in the next 30 daysJuly 2025 Decliners & Consistent Growth Equity Picks - newser.com
Will Pliant Therapeutics Inc. bounce back from current supportJuly 2025 PostEarnings & Community Consensus Trade Alerts - newser.com
Price momentum metrics for Pliant Therapeutics Inc. explainedJuly 2025 Breakouts & Free Community Consensus Stock Picks - newser.com
Can you recover from losses in Pliant Therapeutics Inc.Volume Spike & Weekly Watchlist of Top Performers - newser.com
What analysts say about Pliant Therapeutics Inc stockDividend Cut Warnings & Low Risk Investment Plans - earlytimes.in
Pliant Therapeutics' (PLRX) Underweight Rating Reiterated at JPMorgan Chase & Co. - MarketBeat
JPMorgan downgrades Pliant Therapeutics stock rating to Underweight from Neutral - Investing.com Canada
Pliant Therapeutics Shares Fall After JPMorgan Downgrade - MarketScreener
Pliant Therapeutics Inc. stock outlook for YEARMarket Growth Review & Capital Protection Trade Alerts - newser.com
Allogene, Pliant down as J.P. Morgan cuts to Underweight on uncertain outlook - Seeking Alpha
JPMorgan Downgrades Pliant Therapeutics to Underweight From Neutral - MarketScreener
PLRX Downgraded by JP Morgan: Today's Key Analyst Rating Update - GuruFocus
Order flow analysis tools used on Pliant Therapeutics Inc.July 2025 Intraday Action & Community Consensus Stock Picks - newser.com
Pliant Therapeutics (NASDAQ:PLRX) Receives "Sell (E+)" Rating from Weiss Ratings - MarketBeat
Does Pliant Therapeutics Inc. stock trade at a discount to peersTrade Risk Assessment & Long-Term Safe Return Strategies - newser.com
Is Pliant Therapeutics Inc. (9PT) stock testing key supportPortfolio Growth Summary & Accurate Buy Signal Notifications - newser.com
Is Pliant Therapeutics Inc. (9PT) stock a top pick for value investorsGlobal Markets & Free Reliable Trade Execution Plans - newser.com
Detecting price anomalies in Pliant Therapeutics Inc. with AIJuly 2025 Big Picture & AI Powered Buy/Sell Recommendations - newser.com
Evaluating Pliant Therapeutics Inc. with trendline analysis2025 Volume Leaders & High Conviction Investment Ideas - newser.com
Why Pliant Therapeutics Inc. (9PT) stock attracts wealthy investorsJuly 2025 PostEarnings & Reliable Price Breakout Alerts - newser.com
How sustainable is Pliant Therapeutics Inc. stock dividend payoutJobs Report & Free Technical Pattern Based Buy Signals - newser.com
Published on: 2025-10-03 01:17:50 - newser.com
How Pliant Therapeutics Inc. (9PT) stock reacts to new regulationsEarnings Recap Report & Consistent Return Strategy Ideas - newser.com
Applying big data sentiment scoring on Pliant Therapeutics Inc.Gold Moves & Low Risk High Reward Trade Ideas - newser.com
Technical analysis overview for Pliant Therapeutics Inc. stockQuarterly Performance Summary & Verified Chart Pattern Trade Signals - newser.com
Will Pliant Therapeutics Inc. (9PT) stock keep raising dividendsQuarterly Portfolio Report & Trade Opportunity Analysis - newser.com
Visualizing Pliant Therapeutics Inc. stock with heatmaps2025 Trade Ideas & Expert Verified Stock Movement Alerts - newser.com
Finanzdaten der Pliant Therapeutics Inc-Aktie (PLRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pliant Therapeutics Inc-Aktie (PLRX) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Cummings Keith Lamont | Chief Financial Officer |
Jan 17 '25 |
Sale |
11.20 |
20,148 |
225,680 |
262,608 |
Hull Hans | Chief Business Officer |
Jan 17 '25 |
Sale |
11.20 |
15,936 |
178,501 |
211,558 |
Lefebvre Eric | Chief Medical Officer |
Jan 17 '25 |
Sale |
11.20 |
18,478 |
206,974 |
194,574 |
Cheung Lily | Chief Human Resource Officer |
Jan 17 '25 |
Sale |
11.20 |
3,740 |
41,892 |
24,550 |
Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 17 '25 |
Sale |
11.20 |
13,270 |
148,639 |
80,774 |
Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 22 '25 |
Sale |
10.99 |
10,230 |
112,462 |
70,544 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):